Effect of pneumococcal conjugate vaccination in uruguay, a middle-income Country

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Gabarrot, Gabriela GarcÍa ^a   Vega, Mariana Ló Pez ^a   Giffoni, Gabriel Pé Rez ^a   Ndez, Silvia Herná ^a   Cardinal, Pablo ^b   Lix, Viviana Fé ^a   Gabastou, Jean Marc ^c   Camou, Teresa ^a  

^a Departamento de Laboratorios   (Uruguay)

^b Centro de Terapia Intensiva   (Uruguay)

^c PAN AMERICAN HEALTH ORGANIZATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; BACTEREMIA; CHILD; COHORT ANALYSIS; FATALITY; HUMAN; INCIDENCE; INVASIVE PNEUMOCOCCAL INFECTION; MAJOR CLINICAL STUDY; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; RETROSPECTIVE STUDY; SEPSIS; SEROTYPE; STREPTOCOCCUS PNEUMONIA; URUGUAY; VACCINATION;

EID: 84910149178     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112337     Document Type: Article

References (31)

1. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. (2003) Decline in invasive pneumococcal disease after the introduction of proteinpolysaccharide conjugate vaccine. N Engl J Med 348: 1737-1746.
2. Obaro SK, Adegbola RA, Banya WA, Greenwood BM (1996) Carriage of pneumococci after pneumococcal vaccination. Lancet 348: 271-272.
3. Weinberger DM, Malley R, Lipsitch M (2011) Serotype replacement in disease after pneumococcal vaccination. Lancet 378: 1962-1973.
4. Brueggemann AB, Pai R, Crook DW, Beall B (2007) Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog 3: e168.
5. Bettinger JA, Scheifele DW, Kellner JD, Halperin SA, Vaudry W, et al. (2010) The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000-2007. Vaccine 28: 2130-2136.
6. Di Fabio JL, Castaneda E, Agudelo CI, De La Hoz F, Hortal M, et al. (2001) Evolution of Streptococcus pneumoniae serotypes and penicillin susceptibility in Latin America, Sireva-Vigia Group, 1993 to 1999. PAHO Sireva-Vigia Study Group. Pan American Health Organization. Pediatr Infect Dis J 20: 959-967.
7. Camou T, Palacio R, Di Fabio JL, Hortal M (2003) Invasive pneumococcal diseases in Uruguayan children: comparison between serotype distribution and conjugate vaccine formulations. Vaccine 21: 2093-2096.
8. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, et al. (2010) Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201: 32-41.
9. Instituto Nacional de Estadística. Proyecciones de población. Uruguay. Available at www.ine.gub.uy Accessed July 2013.
10. Picon T, Alonso L, Garcia Gabarrot G, Speranza N, Casas M, et al. (2013) Effectiveness of the 7-valent pneumococcal conjugate vaccine against vaccinetype invasive disease among children in Uruguay: an evaluation using existing data. Vaccine 31 Suppl 3: C109-113.
11. Comisión Honoraria para la Lucha Antituberculosa y enfermedades prevalentes. Programa Nacional Operativo de Inmunizaciones. Available at www.msp.gub. uy. Accessed July 2013.
12. Mogdasy MC, Camou T, Fajardo C, Hortal M (1992) Colonizing and invasive strains of Streptococcus pneumoniae in Uruguayan children: type distribution and patterns of antibiotic resistance. Pediatr Infect Dis J 11: 648-652.
13. Hortal M, Algorta G, Bianchi I, Borthagaray G, Cestau I, et al. (1997) Capsular type distribution and susceptibility to antibiotics of Streptococcus pneumoniae clinical strains isolated from Uruguayan children with systemic infections. Pneumococcus Study Group. Microb Drug Resist 3: 159-163.
14. Lovgren M, Talbot JA, Brandileone MC, Casagrande ST, Agudelo CI, et al. (2007) Evolution of an international external quality assurance model to support laboratory investigation of Streptococcus pneumoniae, developed for the SIREVA project in Latin America, from 1993 to 2005. J Clin Microbiol 45: 3184-3190.
15. Gabastou JM, Agudelo CI, Brandileone MC, Castaneda E, de Lemos AP, et al. (2008) [Characterization of invasive isolates of S. pneumoniae, H. influenzae, and N. meningitidis in Latin America and the Caribbean: SIREVA II, 2000- 2005]. Rev Panam Salud Publica 24: 1-15.
16. Carvalho G, Pimenta FC, Gertz RE, Jr., Joshi HH, Trujillo AA, et al. (2009) PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. J Clin Microbiol 47: 554-559.
17. Epinfo Software. Version 3.5.4. Available at wwwn.cdc.gov/epiinfo.
18. Isaacman DJ, McIntosh ED, Reinert RR (2010) Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 14: e197-209.
19. Karstaedt AS, Khoosal M, Crewe-Brown HH (2000) Pneumococcal bacteremia during a decade in children in Soweto, South Africa. Pediatr Infect Dis J 19: 454-457.
20. Cardinal-Fernandez P, Garcia Gabarrot G, Echeverria P, Zum G, Hurtado J, et al. (2013) Clinical and microbiological aspects of acute community-acquired pneumonia due to Streptococcus pneumoniae. Rev Clin Esp 213: 88-96.
21. Black S, France EK, Isaacman D, Bracken L, Lewis E, et al. (2007) Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 26: 771-777.
22. Castaneda E, Agudelo CI, Regueira M, Corso A, Brandileone MC, et al. (2009) Laboratory-based surveillance of Streptococcus pneumoniae invasive disease in children in 10 Latin American countries: a SIREVA II project, 2000-2005. Pediatr Infect Dis J 28: e265-270.
23. Pirez MC, Algorta G, Cedres A, Sobrero H, Varela A, et al. (2011) Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay. Pediatr Infect Dis J 30: 669-674.
24. Hortal M, Estevan M, Laurani H, Iraola I, Meny M (2012) Hospitalized children with pneumonia in Uruguay: pre and post introduction of 7 and 13- valent pneumococcal conjugated vaccines into the National Immunization Program. Vaccine 30: 4934-4938.
25. Miller E, Andrews NJ, Waight PA, Slack MP, George RC (2011) Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 29: 9127-9131.
26. Harboe ZB, Benfield TL, Valentiner-Branth P, Hjuler T, Lambertsen L, et al. (2010) Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 50: 329-337.
27. Esposito S, Tansey S, Thompson A, Razmpour A, Liang J, et al. (2010) Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol 17: 1017-1026.
28. Wenger JD, Zulz T, Bruden D, Singleton R, Bruce MG, et al. (2010) Invasive pneumococcal disease in Alaskan children: impact of the seven-valent pneumococcal conjugate vaccine and the role of water supply. Pediatr Infect Dis J 29: 251-256.
29. Lehmann D, Willis J, Moore HC, Giele C, Murphy D, et al. (2010) The changing epidemiology of invasive pneumococcal disease in aboriginal and nonaboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis 50: 1477-1486.
30. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, et al. (2013) Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.). Emerg Infect Dis 19: 1074-1083.
31. World Health Organization (2012) Pneumococcal vaccines: WHO position paper 2012. 129-144. p.